SCHEMBL5651378

SCHEMBL5651378

CCOC(=O)c1sc2[nH]c(=O)ccc2c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
HPGD P15428 7/20 0.50
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CDC7 O00311 2/20 0.47
DBF4 Q9UBU7 2/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GRM6 O15303 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
DHODH Q02127 2/20 0.46
CYP2C9 P11712 1/20 0.46
LMNA P02545 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648088 0.88 MAPT (0.49) ALDH1A1HPGDKDM4ESMN1; SMN2MAPT
SCHEMBL2948992 0.82 DHODH (0.51) ALDH1A1HPGDKDM4ESMN1; SMN2MAPT
SCHEMBL5648879 0.81 KDM4E (0.41) ALDH1A1HPGDKDM4EMAPTTDP1
SCHEMBL1266729 0.81 MAPT (0.46) ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2
SCHEMBL5653775 0.78 CDC7 (0.41) ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2
SCHEMBL1190734 0.77 CDC7 (0.47) MAPTCDC7DBF4TRPM8LMNA
SCHEMBL16429545 0.74 ALDH1A1 (0.55) ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2
SCHEMBL10487739 0.74 CDC7 (0.58) ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2
SCHEMBL25205779 0.74 HPGD (0.46) ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2
SCHEMBL5650136 0.74 MAPT (0.51) ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ALDH1A1 1498/4885HPGD 1929/4885HSD17B10 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.